Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We sought to determine whether the biomarkers of chronic inflammation predict cognitive decline in a prospective observational study. We measured baseline serum soluble urokinase plasminogen activator receptor (suPAR) and high sensitivity C-reactive protein (hs-CRP) levels in 282 participants of the University of Michigan Memory and Aging Project. Cognitive function was measured using the Montreal Cognitive Assessment (MoCA) and the Clinical Dementia Rating (CDR) scale for up to five time points. SuPAR and hs-CRP levels were not significantly higher in participants with mild cognitive impairment ( = 97) or dementia ( = 59), compared to those with normal cognitive function ( = 126). Overall, 14% of participants experienced significant cognitive decline over the study period. The change in MoCA or CDR scores over time did not differ significantly according to baseline suPAR or hs-CRP levels. Chronic systemic inflammation, as measured by serum suPAR or hs-CRP levels, is unlikely to contribute significantly to cognitive decline.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964918 | PMC |
| http://dx.doi.org/10.1002/dad2.12568 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting cognitive decline in Alzheimer's disease: A real-life proof-of-principle study on multimodal assessment.
J Alzheimers Dis
September 2025
Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Università Campus Bio-Medico di Roma, Roma, Italy.
BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder. While AD diagnosis traditionally relies on clinical criteria, recent trends favor a precise biological definition. Existing biomarkers efficiently detect AD pathology but inadequately reflect the extent of cognitive impairment or disease heterogeneity.
View Article and Find Full Text PDFA real-world study on the safety and efficacy of therapeutic plasma exchange in patients with Alzheimer's disease.
J Alzheimers Dis
September 2025
Paula Costa-Urrutia Medical Affairs, Terumo BCT, Edificio Think MVD, Montevideo, Uruguay.
BackgroundTherapeutic plasma exchange (TPE) with albumin replacement has emerged as a potential treatment for Alzheimer's disease (AD). The AMBAR trial showed that TPE could slow cognitive and functional decline, along with changes in core and inflammatory biomarkers in cerebrospinal fluid.ObjectiveTo evaluate the safety and effectiveness of TPE in a real-world setting in Argentina.
View Article and Find Full Text PDFAssociated Factors of Cognitive Frailty in People Living with HIV Aged 50 and Older: A Cross-Sectional Study.
Infect Dis Ther
September 2025
Department of Nursing, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Introduction: Cognitive frailty (CF), which typically precedes dementia and functional decline, serves as a more robust predictor of adverse health outcomes compared to physical frailty alone, representing a critical challenge in promoting healthy aging among older people living with HIV (PLWH) aged ≥ 50 years. This study aimed to investigate the prevalence of cognitive frailty and identify its associated factors among PLWH aged ≥ 50 years.
Methods: A convenience sample of 344 PLWH ≥ 50 years was recruited from a tertiary Grade A hospital in Zunyi, China.
Cerebellar Stimulation Modulates Reward Processing: A High-definition Transcranial Direct Current Stimulation Study.
Cerebellum
September 2025
Neuropsychology and Applied Cognitive Neuroscience Laboratory, State Key Laboratory of Cognitive Science and Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.
Reward processing involves several components, including reward anticipation, cost-effort computation, reward consumption, reward sensitivity, and reward learning. Recent research has highlighted the cerebellum's role in reward processing. This study aimed to investigate the effects of cerebellar stimulation on reward processing using high-definition transcranial direct current stimulation (HD-tDCS).
View Article and Find Full Text PDF4-aminopyridine exerts anxiolytic and pro-cognitive effects in mice model of medial prefrontal cortex ischemia.
Metab Brain Dis
September 2025
Department of Neuroscience, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Brain ischemia is a major global cause of disability, frequently leading to psychoneurological issues. This study investigates the effects of 4-aminopyridine (4-AP) on anxiety, cognitive impairment, and potential underlying mechanisms in a mouse model of medial prefrontal cortex (mPFC) ischemia. Mice with mPFC ischemia were treated with normal saline (NS) or different doses of 4-AP (250, 500, and 1000 µg/kg) for 14 consecutive days.
View Article and Find Full Text PDF